Disease · MONDO_0005191

metastatic melanoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. metastatic melanoma. Diseases, record MONDO_0005191. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005191

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: metastatic melanoma; Open Targets
Open Targets ID: MONDO_0005191; Open Targets
Other names: metastatic malignant melanoma; Open Targets
NCI Thesaurus: C8925; NCI Thesaurus
Highest stage of its drugs: Approval, for 12 of its 52 drugs, from DailyMed, FDA and TTD; Open Targets

Drugs52

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ALDESLEUKIN	CHEMBL1201438	Protein	Approval	DailyMed	10	9	9	Drugs and targets
IPILIMUMAB	CHEMBL1789844	Antibody	Approval	DailyMed	5	4	3	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Approval	DailyMed	5	4	3	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Approval	DailyMed	5	4	3	Drugs and targets
VEMURAFENIB	CHEMBL1229517	Small molecule	Approval	DailyMed	4	3	3	Drugs and targets
DACARBAZINE	CHEMBL476	Small molecule	Approval	DailyMed	4	1	1	Drugs and targets
BINIMETINIB	CHEMBL3187723	Small molecule	Approval	FDA	1	0	0	Drugs and targets
COBIMETINIB FUMARATE	CHEMBL2364607	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
DABRAFENIB MESYLATE	CHEMBL2105729	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
ENCORAFENIB	CHEMBL3301612	Small molecule	Approval	FDA	1	0	0	Drugs and targets

1 to 10 of 52

See all 52 drugs

Targets81

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	9	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Approval	https://conductscience.org/library/genes/5133	Drugs and targets
MAP2K1	Dual specificity mitogen-activated protein kinase kinase 1	5	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor	Approval	https://conductscience.org/library/genes/5604	Drugs and targets
MAP2K2	Dual specificity mitogen-activated protein kinase kinase 2	5	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor	Approval	https://conductscience.org/library/genes/5605	Drugs and targets
BRAF	Serine/threonine-protein kinase B-raf	4	Serine/threonine-protein kinase B-raf inhibitor	Approval	https://conductscience.org/library/genes/673	Drugs and targets
CSF1R	Macrophage colony-stimulating factor 1 receptor	2	Macrophage colony stimulating factor receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/1436	Drugs and targets
CTLA4	Cytotoxic T-lymphocyte protein 4	2	Cytotoxic T-lymphocyte protein 4 inhibitor	Approval	https://conductscience.org/library/genes/1493	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/2324	Drugs and targets
KDR	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/3791	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	2	Stem cell growth factor receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/3815	Drugs and targets

1 to 10 of 81

See all 81 targets

Trials29

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01006252	A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma	Phase 3	336	2018-07-17	Melanoma	PACLITAXEL, TASISULAM SODIUM	Its record names the disease	ClinicalTrials.gov
NCT00513604	Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma	Phase 2	158	2013-05-27	Melanoma, Malignant Melanoma, Melanoma, Experimental, Experimental Melanomas	ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE	Its record names the disease	ClinicalTrials.gov
NCT03123783	CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab	Phase 1/2	140	2023-12-05	Cancer, Non Small Cell Lung Cancer Metastatic, Metastatic Melanoma, Neoplasm of Lung, Melanoma	NIVOLUMAB, SOTIGALIMAB	Its record names the disease	ClinicalTrials.gov
NCT01993719	Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma	Phase 2	33	2023-01-18	Metastatic Melanoma	ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02009397	A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients	Phase 1/2	27	2021-11-22	Metastatic Melanoma	IPILIMUMAB, REGRAMOSTIM	Its record names the disease	ClinicalTrials.gov
NCT01218867	CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer	Phase 1/2	24	2016-07-22	Metastatic Cancer, Metastatic Melanoma, Renal Cancer	ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE	Its record names the disease	ClinicalTrials.gov
NCT02111850	T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive	Phase 1/2	21	2022-03-29	Cervical Cancer, Renal Cancer, Urothelial Cancer, Melanoma, Breast Cancer	ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE	Its record names the disease	ClinicalTrials.gov
NCT01124734	High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma	Phase 2	17	2019-02-12	Malignant Melanoma	ALDESLEUKIN, TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov
NCT02354690	Vemurafenib and TIL Therapy for Metastatic Melanoma	Phase 1/2	13	2020-02-24	Metastatic Melanoma	ALDESLEUKIN, VEMURAFENIB	Its record names the disease	ClinicalTrials.gov
NCT03816332	Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers	Phase 1	12	2023-06-27	Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Basal Cell Carcinoma, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Unresectable Basal Cell Carcinoma, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma	IPILIMUMAB, NIVOLUMAB, PREDNISONE, TACROLIMUS	Its record names the disease	ClinicalTrials.gov

1 to 10 of 29

See all 29 trials

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Tasisulam-sodium vs Paclitaxel: serious adverse events	53 of 164	44 of 161	325	NCT01006252	Trial comparisons
Course 1 Cycle 1 vs Course 1 Cycle 2: Safety and Toxicity of H-D IL-2 Followed by Low Dose Temozolomide	0 of 17	0 of 17	34	NCT01124734	Trial comparisons
Course 1 Cycle 1 vs Course 1 Cycle 2: deaths from any cause	0 of 17	9 of 17	34	NCT01124734	Trial comparisons
Course 1 Cycle 1 vs Course 1 Cycle 2: serious adverse events	1 of 17	1 of 17	34	NCT01124734	Trial comparisons
Nivolumab, Tacrolimus, and Prednisone vs Ipilimumab, Nivolumab, Tacrolimus, and Prednisone: deaths from any cause	4 of 10	3 of 6	16	NCT03816332	Trial comparisons
Nivolumab, Tacrolimus, and Prednisone vs Ipilimumab, Nivolumab, Tacrolimus, and Prednisone: serious adverse events	6 of 10	6 of 6	16	NCT03816332	Trial comparisons

Papers from its trials14

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
28497258	RESULT	1	PubMed
19918923	RESULT	1	PubMed
12843799	RESULT	1	PubMed
10850352	RESULT	1	PubMed
8399072	RESULT	1	PubMed
38252910	DERIVED	1	PubMed
37131154	DERIVED	1	PubMed
36821617	DERIVED	1	PubMed
32819972	DERIVED	1	PubMed
32747469	DERIVED	1	PubMed

1 to 10 of 14

See all 14 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005191

GET https://conductscience.org/api/diseases/v1/MONDO_0005191/drugs?page=2

API reference For AI assistants